diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-6117diaendo-6117Research ArticleСтатьиArticlesИспользование инкретинов в лечении сахарного диабета 2 типа - вчерашняя мечта, близкая к реальности сегодняIspol'zovanie inkretinov v lecheniisakharnogo diabeta 2 tipa - vcherashnyaya mechta,blizkaya k real'nosti segodnyaМкртумянАшот МусаеловичMkrtumyanAshot Musaelovich-БирюковаЕлена ВалерьевнаBiryukovaElena Valer'evna-Московский государственный медико-стоматологический университет, Москва20061506200692№2 (2006)3439Copyright © Мкртумян А.М., Бирюкова Е.В., 20062006Мкртумян А.М., Бирюкова Е.В.Mkrtumyan A.M., Biryukova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/6117

Регуляция гомеостаза глюкозы осуществляется сложной мультигормональной системой, включающей гормоны поджелудочной железы и гормоны-инкретины. После открытия в 1902 г. секретина Старлинг предположил, что сигналы, возникающие в желудочно-кишечном тракте (ЖКТ) после поступления нутриентов, активно влияют на эндокринный ответ поджелудочной железы. В 1930 г. Labbarre ввел термин ?инкретин?, обозначив им гормональную активность кишечника, которая повышает эндокринную секрецию поджелудочной железы.

инкретинылечениесахарный диабет 2 типаReferencesAronoff SL, Berkowitz K, Shreiner B et al. Glucose metabolism and regulation: beyond insulin and glucagon. // Diabetes Spectrum. 2004;17:183-190Aronoff SL, Berkowitz K, Shreiner B et al. Glucose metabolism and regulation: beyond insulin and glucagon. // Diabetes Spectrum. 2004;17:183-190Kreymann B, Williams G, Ghatei MA. Glucagon-like peptide 1 (7-36): a physiological incretin in man. // Lancet 1987;2:1300-4Kreymann B, Williams G, Ghatei MA. Glucagon-like peptide 1 (7-36): a physiological incretin in man. // Lancet 1987;2:1300-4Perley M.J., et al. // J. Clin. Invest. 1967; 46: 1954-1962.Perley M.J., et al. // J. Clin. Invest. 1967; 46: 1954-1962.Kieffer TJ, Habener JF. The glucagon-like peptides. // Endocrine Reviews 1999; 20(6):876-913Kieffer TJ, Habener JF. The glucagon-like peptides. // Endocrine Reviews 1999; 20(6):876-913D'Alessio DA, Vahl TP. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. // Am J Physiol Endocrinol Metab. 2004;286:E882-E90D'Alessio DA, Vahl TP. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. // Am J Physiol Endocrinol Metab. 2004;286:E882-E90Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. // Am J Physiol Endocrinol Metab. 2004;287:E 199-E 206Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. // Am J Physiol Endocrinol Metab. 2004;287:E 199-E 206Drucker DJ. Biological action and therapeutic potenctial of the glucagonlike peptides. //Gastroenterology 2002; 122:531-44.Drucker DJ. Biological action and therapeutic potenctial of the glucagonlike peptides. //Gastroenterology 2002; 122:531-44.Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glukagon-like peptide in the pathogenesis of type 2 diabetes. // Diabetes. 2004;53(3):190-6Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glukagon-like peptide in the pathogenesis of type 2 diabetes. // Diabetes. 2004;53(3):190-6Nauck MA, Meier JJ. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. // Regul Pept. 2005;128:135-48Nauck MA, Meier JJ. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. // Regul Pept. 2005;128:135-48Ahren B. GLP-1 and extra-islet effects. // Horm Metab Res. 2004; 36 (11-12):842-5Ahren B. GLP-1 and extra-islet effects. // Horm Metab Res. 2004; 36 (11-12):842-5Egan JM, Meneilly GS, Elahi D. Effects of 1-mo bolus subcutaneous administration exentid-4 in type 2 diabetes. // Am J Physiol Endocrinol Metab. 2003;284:E 1072-E 79Egan JM, Meneilly GS, Elahi D. Effects of 1-mo bolus subcutaneous administration exentid-4 in type 2 diabetes. // Am J Physiol Endocrinol Metab. 2003;284:E 1072-E 79Dungan K., Buse J B. Glucagon-like peptide 1-based therapies for type 2 diabetes: a focus on exenatide // Clinical diabetes 2005; 23: 56-62Dungan K., Buse J B. Glucagon-like peptide 1-based therapies for type 2 diabetes: a focus on exenatide // Clinical diabetes 2005; 23: 56-62Nauck MA, Meier JJ, Creutzfeldt. Incretins and their analogues as new antidiabetic agent // Drug News Perspect -2003: 413-22Nauck MA, Meier JJ, Creutzfeldt. Incretins and their analogues as new antidiabetic agent // Drug News Perspect -2003: 413-22McIntyre N, Holdsworth CD, Turner DS. Intestinal factors in the control of insulin secretion/ // J Clin Endocrinol 1965;25:1317-24McIntyre N, Holdsworth CD, Turner DS. Intestinal factors in the control of insulin secretion/ // J Clin Endocrinol 1965;25:1317-24Holst JJ. Treatment of type 2 diabetes mellitus based on glucagons-like peptide-1. // Expert Opin Investig Drugs. 1999;8(9):1409-15Holst JJ. Treatment of type 2 diabetes mellitus based on glucagons-like peptide-1. // Expert Opin Investig Drugs. 1999;8(9):1409-15Nauck MA. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.// Horm Metab Res. 2004;36:852-8Nauck MA. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.// Horm Metab Res. 2004;36:852-8Henriksen DB, Alexandersen P, Bjarnason NH et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. // J Bone Miner Res. 2003;18(12):2180-9Henriksen DB, Alexandersen P, Bjarnason NH et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. // J Bone Miner Res. 2003;18(12):2180-9Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. //Diabetes Care. 2003;26:2929-40Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. //Diabetes Care. 2003;26:2929-40Takei I, Kasatani T. Future therapy of diabetes mellitus. // Biomedicine & Pharmacotherapy. 2004;58:578-81Takei I, Kasatani T. Future therapy of diabetes mellitus. // Biomedicine & Pharmacotherapy. 2004;58:578-81Flint A, Raben A, Astrup A et al. Glucagon-like peptide 1promotes satiety and suppresses energy intake in human // J Clin Invest 1998; 101: 515-20Flint A, Raben A, Astrup A et al. Glucagon-like peptide 1promotes satiety and suppresses energy intake in human // J Clin Invest 1998; 101: 515-20Jeibmann A, Zahedi S., Simoni M, et al. Glucagon-like peptide 1 reduses the pulsatile component of testosterone secretion in healthy males.// Eur J Clin Invest. 2005;35(9):565-72Jeibmann A, Zahedi S., Simoni M, et al. Glucagon-like peptide 1 reduses the pulsatile component of testosterone secretion in healthy males.// Eur J Clin Invest. 2005;35(9):565-72Gutzwiller JP, Tschopp S, Bock A et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.// J Clin Endocrinol Metab. 2004;89(6):3055-61Gutzwiller JP, Tschopp S, Bock A et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.// J Clin Endocrinol Metab. 2004;89(6):3055-61Heine RJ, Van Gaal LF, Johns D, et al. .// Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med. 2005;143(8):559-69Heine RJ, Van Gaal LF, Johns D, et al. .// Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med. 2005;143(8):559-69Kolterman OG, Buse JB, Fineman MS et al. Syntetic exentid-4 (exenatide) significantly redues postprandial and fasting plazma glucose in subjects with type 2 diabetes. // J Clin Endocrinol Metab. 2003;88:3082-9Kolterman OG, Buse JB, Fineman MS et al. Syntetic exentid-4 (exenatide) significantly redues postprandial and fasting plazma glucose in subjects with type 2 diabetes. // J Clin Endocrinol Metab. 2003;88:3082-9

The authors declare that there are no conflicts of interest present.